License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~
~ APB-102 and uniQure’s c9orf72-ALS program have the potential to address most inherited forms of ALS ~
~ uniQure plans to initiate a Phase I/II trial of APB-102 in the second half of 2023 ~
https://finance.yahoo.com/news/uniqure-apic-bio-enter-global-120500790.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.